Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Julia, Zack"'
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 9, Pp n/a-n/a (2024)
Abstract A drug–drug interaction (DDI) study was conducted to evaluate the effect of icenticaftor (QBW251) on the pharmacokinetics (PK) of a 5‐probe cytochrome P450 (CYP) substrate cocktail, guided by in vitro studies in human hepatocytes and liv
Externí odkaz:
https://doaj.org/article/47ca3c2c5720421f9edc683f47eb2c5a
Autor:
William T. Prince, Vinay Kumar Venishetty, Jean Lecot, Kasra Shakeri‐Nejad, Cathy Gray, Amanda Taylor, Ganesh R. Iyer, Julia Zack
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 10, Pp 1758-1767 (2023)
Abstract Triclabendazole is an effective and well‐tolerated treatment for human fascioliasis. A placebo‐ and positive‐controlled, four‐sequence by four‐period crossover study was conducted in 45 healthy participants to assess the effect of
Externí odkaz:
https://doaj.org/article/64c515edc6524a60806e568d0973610f
Autor:
Swarupa Kulkarni, Xinting Wang, Jing Yu, Ramachandra Sangana, Monish Jain, Christian Bartels, Julia Zack
Publikováno v:
Drug Research. 71:326-334
Aim The objective of this analysis was to characterize the population pharmacokinetics (PK) of fevipiprant in asthma patients and to evaluate the effect of baseline covariates on the PK of fevipiprant. Methods PK data from 1281 healthy subjects or as
Autor:
Florence Hourcade-Potelleret, Tirtha Sengupta, Alex Allepuz, Julia Zack, Masahiko Sato, Matthias Hoch, Paola Aimone, Michelle Quinlan
Publikováno v:
Journal of clinical pharmacologyReferences. 61(11)
Asciminib is an investigational, first-in-class, specifically targeting the ABL myristoyl pocket (STAMP) inhibitor of BCR-ABL1 with a new mechanism of action compared with approved ATP-competitive tyrosine kinase inhibitors. This report describes the
Autor:
Matthias Hoch, Julia Zack, Stephanie Kay Dodd, Paola Aimone, Felix Huth, Michelle Quinlan, Sofia Forte, Florence Hourcade-Potelleret
Publikováno v:
Clinical pharmacology in drug developmentReferences. 11(2)
Asciminib, a first-in-class, Specifically Targeting the Abelson kinase Myristoyl Pocket (STAMP) inhibitor with the potential to overcome resistance to adenosine triphosphate-competitive tyrosine kinase inhibitors, is being investigated in leukemia as
Autor:
Ori Ben-Yehuda, Martine Allard, Nicola Pannacciulli, Heather Zhang, Phil Jochelson, Jolene Berg, Axel Juan, Julia Zack, Yongwu Shao, Mildred Gottwald
Publikováno v:
Clinical Pharmacology in Drug Development. 4:121-129
Ranolazine and metformin may be frequently co-administered in subjects with chronic angina and co-morbid type 2 diabetes mellitus (T2DM). The potential for a drug-drug interaction was explored in two phase 1 clinical studies in subjects with T2DM to
Autor:
Gregory E. Wilding, Rocco C. Venuto, Robin DiFrancesco, Nicolae Leca, Ryan T. Danison, Aijaz Gundroo, Julia Zack, Kathryn Gillis, Kathleen M. Tornatore, Kiran Dole, Daniel A. Brazeau
Publikováno v:
The Journal of Clinical Pharmacology. 53:1039-1047
Cyclosporine exhibits pharmacokinetic and pharmacodynamic variability in renal transplant recipients (RTR) attributed to P-glycoprotein (P-gp), an ABCB1 efflux transporter that influences bioavailability and intracellular distribution. Data on race a
Autor:
Julia Zack, Justus Bingham, Peter Staehr, Xuegong Wang, Yu L. Ho, Luiz Belardinelli, Arvinder Dhalla
Publikováno v:
The Journal of Clinical Pharmacology. 53:385-392
GS-9667, a new selective, partial agonist of the A(1) adenosine receptor (AR), may represent an effective therapy for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA). The objectives of the studies were to evaluate the e
Publikováno v:
The Journal of Clinical Pharmacology. 52:1784-1805
The authors review the basic pharmacology and potential for adverse drug-drug interactions (DDIs) of bosentan and ambrisentan, the 2 endothelin receptor antagonists currently approved for pulmonary arterial hypertension (PAH) treatment. Bosentan, an
Autor:
Julia Zack, Ryan T. Danison, Kathleen M. Tornatore, Robin DiFrancesco, Alan Forrest, Nicolae Leca, Gregory E. Wilding, Rocco C. Venuto, Aijaz C. Gundroo, Patcharaporn Sudchada, Kiran Dole, Kris Attwood
Publikováno v:
The Journal of Clinical Pharmacology. 51:1213-1222
Renal transplant recipients exhibit variability in mycophenolic acid (MPA) and MPA glucuronide (MPAG) pharmacokinetics, which are influenced by clinical and demographic factors. Racial influence on MPA and MPAG pharmacokinetics was investigated in 53